Are Peptides Legal in Canada?

Peptides in Canada are regulated as drugs under the Food and Drugs Act (R.S.C. 1985, c. F-27), with an additional layer from the Controlled Drugs and Substances Act (S.C. 1996, c. 19) for specific compounds like HGH. Together, these laws create a framework that is more defined than the United States but less restrictive than Australia.

Under Section 2 of the Food and Drugs Act, a substance is classified as a “drug” if it is represented for use in the diagnosis, treatment, mitigation, or prevention of disease, or for restoring, correcting, or modifying organic functions in humans. This definition is broad by design – it captures intent, not just chemical structure. A peptide vial labelled “for research use only” can still be classified as a drug if the vendor’s website, marketing materials, or social media content implies therapeutic use. As Health Canada stated in its April 2026 advisory, a “research use only” label “does not make them legal or exempt from regulatory requirements.”

Any drug sold in Canada requires a Drug Identification Number (DIN) – an eight-digit code printed on the label confirming that Health Canada has assessed the product for safety, efficacy, and quality. Peptides with DIN authorization include semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro), insulin formulations, octreotide, and somatropin. The vast majority of research peptides – BPC-157, TB-500, CJC-1295, Ipamorelin, Semax, Selank, and dozens more – have no DIN, no pending DIN application, and no realistic pathway to obtaining one.

The bottom line: In Canada, the DIN is the single legal dividing line between an authorized drug and an unauthorized one – if the label does not show an eight-digit DIN, the product has not been assessed by Health Canada.

The Controlled Drugs and Substances Act

A separate layer of regulation comes from the Controlled Drugs and Substances Act (CDSA), which governs narcotics and controlled substances through eight schedules. Human growth hormone (somatotropin) and anabolic steroids are listed in Schedule IV of the CDSA. Under Schedule IV, personal possession is legal, but trafficking – defined broadly to include any unauthorized sale, distribution, or transfer – is a criminal offence carrying penalties of up to 18 months’ imprisonment on summary conviction or up to three years on indictment.

Most commonly discussed research peptides are not CDSA-scheduled. BPC-157, TB-500, CJC-1295, Ipamorelin, sermorelin, thymosin alpha-1, and growth hormone secretagogues (GHRPs) do not appear in any CDSA schedule as of May 2026. This is an important distinction: these peptides are regulated as unauthorized drugs under the Food and Drugs Act (a civil/administrative framework), not as controlled substances under the CDSA (a criminal framework). The practical difference is that possessing an unauthorized drug without a DIN is generally not a criminal offence for the buyer, whereas trafficking a Schedule IV substance is.

Canadian compounding pharmacies can legally prepare peptide formulations that lack a DIN, provided they operate within the compounding framework set out by Health Canada’s Policy on Manufacturing and Compounding Drug Products (POL-0051). This requires the pharmacy to be provincially licensed, operate under the supervision of a licensed pharmacist, and fill a valid prescription from a Canadian-licensed physician.

In practice, this means a Canadian doctor can prescribe compounded BPC-157, sermorelin, CJC-1295/Ipamorelin, or thymosin alpha-1 when they assess clinical need and no DIN-authorized alternative exists. Functional medicine practitioners, integrative physicians, and anti-aging specialists in Canada routinely use this pathway. The compounding pharmacy then sources pharmaceutical-grade raw material, prepares the formulation to USP 795/797 standards, and dispenses it against the prescription.

The critical distinction is between compounding and manufacturing. Under POL-0051, compounding is patient-specific and prescription-driven. If a pharmacy begins producing peptide formulations in bulk without individual prescriptions – or ships them across provincial borders at scale – it crosses into manufacturing, which requires a Drug Establishment Licence (DEL) and compliance with Good Manufacturing Practice (GMP) standards. This line has been tested in enforcement actions: Health Canada’s 2013 interim regulatory direction clarified that compounding activities must either occur in a hospital meeting provincial requirements, occur under the supervision of a provincially licensed pharmacist, or meet federal GMP licensing requirements.

Provincial variation adds another layer. Because pharmacy regulation falls under provincial jurisdiction, compounding rules differ across provinces. Alberta, Ontario, and British Columbia have the most established peptide-prescribing communities among functional medicine practitioners, while Quebec and the Atlantic provinces tend to have less developed compounding infrastructure for these substances.

The bottom line: The compounding pharmacy pathway is the only fully legal route for Canadians to access non-DIN peptides, but it requires a valid prescription from a licensed physician and a compliant compounding pharmacy.

Health Canada’s enforcement against unauthorized peptide vendors has accelerated sharply since mid-2024, following a pattern that mirrors – but operates independently from – the FDA’s parallel crackdown in the United States.

Date	Action	Details
Jun 2024	Quad Inc. seizure (Beloeil, Quebec)	Injectable peptides and bodybuilding drugs seized from Quadragen/Advanced Research websites. Advisory expanded July 2024 to include nootropics (bromantane, omberacetam) and SARMs (RU-58841).
Apr 2025	Prime Research advisory	Unauthorized injectable peptide drugs sold by Prime Research flagged for potential serious health risks.
Aug 2025	Canada Peptide seizure	Health Canada seized 42+ unauthorized injectable peptide products from Canada Peptide. Products included BPC-157, CJC-1295, DSIP, Epitalon, GHK-Cu, HCG, Ipamorelin, KPV, Melanotan I/II, MOTS-C, NAD+, SS-31, TB-500, Retatrutide, and others.
Jan 2026	Counterfeit GLP-1 advisory	Health Canada warned about fake/unauthorized Ozempic and Mounjaro products appearing online.
Apr 9, 2026	Major public advisory	“Think twice before injecting peptides bought online.” Broadest advisory to date. Named 42+ specific peptide compounds. Covered by CBC, Global News, and CP24. College of Physicians and Surgeons of Alberta issued follow-up guidance to physicians.
Apr 18, 2026	CBC follow-up investigation	CBC reporters purchased three unauthorized peptide products online despite the advisory, demonstrating ongoing enforcement gaps.

The August 2025 Canada Peptide seizure was the most detailed enforcement action to date. The company was selling 42+ unauthorized injectable peptide compounds via its website – the full list published by Health Canada included compounds spanning healing (BPC-157, TB-500, KPV, LL-37, thymosin alpha-1), growth hormone secretagogues (CJC-1295, GHRP-2, GHRP-6, hexarelin, ipamorelin, sermorelin, tesamorelin, gonadorelin), longevity bioregulators (epitalon, pinealon, bronchogen, cortagen, livagen, ovagen, prostamax, vilon, vesugen), cognitive peptides (selank, semax, DSIP), fat-loss compounds (AOD9604, GLP-1 (7-37), retatrutide, tirzepatide), and tanning peptides (Melanotan I, Melanotan II). This list represents the broadest set of named peptides in any single regulatory action by a non-US Western regulator.

The April 2026 advisory marked a shift in tone. Rather than targeting a single vendor, Health Canada issued a general public warning against all unauthorized injectable peptides sold online. The advisory specifically noted that wellness influencers were “increasingly pushing peptides as a ‘magical’ product for everything from slowing aging to boosting muscle mass” and warned that unauthorized products carried risks including hormonal imbalance, liver damage, kidney damage, blood clots, and growth of cancerous tumours. The College of Physicians and Surgeons of Alberta (CPSA) responded by issuing guidance to physicians, asking them to actively question patients about non-prescribed injectable products and remain alert to complications.

The bottom line: Health Canada issued more enforcement actions against peptide vendors in the 18 months between mid-2024 and April 2026 than in the preceding decade combined, signalling a permanent regulatory escalation.

The Canada Border Services Agency (CBSA) has the authority to detain and seize any product that does not comply with Canadian drug regulations at the border. For peptides imported without a valid prescription or DIN authorization, CBSA officers can confiscate shipments, and consequences range from product seizure to fines.

CBSA enforcement against peptide imports is considered stricter than equivalent US customs enforcement. Shipments from Chinese and US suppliers are the most commonly intercepted, particularly when they contain unlabelled vials, lack proper customs declarations, or include products that Health Canada has specifically named in advisories. Domestic Canadian suppliers eliminate customs risk entirely, which is why the Canadian research peptide market has increasingly shifted toward domestically stocked inventory rather than cross-border drop-shipping.

The table below summarizes the Canadian regulatory status of commonly discussed peptides. “DIN-authorized” means the compound has completed Health Canada’s approval process and is legally available through standard pharmacy channels. “No DIN” means the compound has not been authorized for sale in Canada as a drug product.

Compound	DIN Status	CDSA Schedule	Access Route
Semaglutide (Ozempic/Wegovy)	DIN-authorized	Not scheduled	Prescription from licensed pharmacy
Tirzepatide (Mounjaro)	DIN-authorized	Not scheduled	Prescription from licensed pharmacy
Somatropin (HGH)	DIN-authorized	Schedule IV	Prescription only. Trafficking is criminal.
BPC-157	No DIN	Not scheduled	Compounding pharmacy with Rx
TB-500	No DIN	Not scheduled	Compounding pharmacy with Rx
CJC-1295 / Ipamorelin	No DIN	Not scheduled	Compounding pharmacy with Rx
Sermorelin	No DIN	Not scheduled	Compounding pharmacy with Rx
Melanotan I / II	No DIN	Not scheduled	No legal access. Named in HC advisories.
PT-141 (Bremelanotide)	No DIN	Not scheduled	Compounding pharmacy with Rx. US FDA approval does not extend to Canada.
Thymosin alpha-1	No DIN	Not scheduled	Compounding pharmacy with Rx

“Research use only” (RUO) labelling is not a legal exemption in Canada. Health Canada has been explicit on this point: a product labelled for research use is not shielded from the Food and Drugs Act if it is sold in a manner that implies, suggests, or facilitates human therapeutic use.

In practice, Health Canada evaluates the totality of how a product is positioned – not just the label. Factors that trigger regulatory attention include websites listing potential health benefits, product pages showing pre-filled syringes or injection supplies, social media posts featuring before/after images, customer reviews describing personal use outcomes, and dosing guidance anywhere in the vendor’s ecosystem. The label on the vial is only one data point; if the surrounding context implies human use, the product is treated as an unauthorized drug.

There is a legitimate research exemption pathway. Canadian academic and institutional researchers can obtain peptides for bona fide research through their institutional framework, typically with approval from a research ethics board. This is a narrow, documented pathway – not the same as a consumer buying vials from a website that happens to print “for research use only” on the label.

The bottom line: The RUO label does not create a parallel legal market for peptides in Canada – it is a compliance tool for legitimate institutional research, not a consumer purchasing exemption.

Enforcement risk in Canada concentrates overwhelmingly on the supply side, not the buyer. Health Canada targets vendors selling unauthorized drugs, not individuals possessing them. No publicly reported case exists of an individual Canadian being criminally charged for purchasing a non-CDSA-scheduled peptide for personal use.

For vendors, however, the legal exposure is significant. Selling an unauthorized drug violates Section 9 of the Food and Drugs Act. The maximum penalty under the Act includes fines of up to CAD $5,000 and/or imprisonment of up to three years on summary conviction. More practically, Health Canada can seize product, issue public advisories naming the company (which effectively destroys the business), and refer cases to the Public Prosecution Service of Canada.

For buyers, the primary risks are: product seizure at the border (CBSA interception), receiving a compliance notice (which creates a file but carries no criminal penalty for non-CDSA substances), and – most importantly – health risks from unregulated products that have not been assessed for safety, quality, or contamination.

Factor	Canada	United States	Australia
Regulatory body	Health Canada	FDA	TGA
Compounding pathway	Yes (provincial pharmacy)	Yes (503A/503B)	Very limited (SAS)
BPC-157 status	Unauthorized (no DIN)	PCAC review pending	Schedule 4 (Rx only)
Melanotan II status	Unauthorized. Named in HC advisory.	Unapproved new drug	Schedule 9 (prohibited)
Personal possession	Rarely prosecuted	Not criminal (FD&C Act)	State penalties apply
Regulatory direction	Tightening (since 2024)	Loosening (2026 reclassification)	Tightening (since 2023)
Border enforcement	CBSA – stricter than US	CBP – selective	ABF – strictest

Canada currently sits between the United States and Australia on the restrictiveness spectrum. Australia explicitly schedules individual peptides (BPC-157 as Schedule 4, Melanotan II as Schedule 9) and imposes state-level criminal penalties for possession. For a detailed breakdown of the Australian system, see our guide to peptide legality in Australia. The US offers a unique 503A/503B compounding pathway that Canada lacks. For details on how the US system works, see our guide to peptide legality in the US.

One area where Canada diverges sharply from the US: there is no equivalent to the FDA’s positive list or category system for compounding. Canadian compounding pharmacies do not need a peptide to appear on a government-approved list before preparing it – they need a valid prescription and compliant pharmacy practices. This is both more flexible (no compound-by-compound approval process) and less defined (no explicit government endorsement of specific compounds for compounding).

US FDA regulatory changes will affect Canadian supply chains in 2026. The April 2026 removal of 12 peptides from Category 2 and referral to PCAC shifts demand patterns, and Canadian compounding pharmacies often source raw materials from the same suppliers as US pharmacies. If US demand shifts due to PCAC outcomes, Canadian supply chains will feel the impact.

Health Canada has not signalled any intent to adopt a compound-specific scheduling system comparable to Australia’s SUSMP. However, the pace of public advisories suggests that regulatory attention to the online peptide market will continue to intensify through 2026. The GLP-1 pipeline – particularly the question of whether compounded semaglutide and tirzepatide products will face additional regulatory restrictions – is also likely to drive further enforcement activity, given the enormous consumer demand and the proliferation of unauthorized products in that space.